Specificity of hypothalamic peptides in the control of behavioral and physiological processes.
This review summarizes two model systems for understanding how brain neurochemicals, in conjunction with peripheral endocrine and metabolic processes, may be active in controlling very different functions in relation to energy and nutrient balance. As proposed, these systems are unquestionably oversimplified; however, they generate testable hypotheses for future investigations that will help to advance and revise these working models, as well as those of other peptide systems in the brain. Under normal conditions, these peptide systems are behaviorally and endocrinologically specific, and they are activated at very different periods of the daily cycle and at different stages of development. However, under pathologic conditions, their specificity and rhythmicity may be greatly disturbed. This occurs in states involving hypercortisolemia along with hyperinsulinemia or insulin deficiency, when these peptide systems become chronically activated. To determine whether this increased activity actually contributes to conditions of hyperphagia and obesity, and, thus, whether a reversal of this neurochemical activity may help in the treatment of these conditions, critical studies with various pharmacological manipulations are required. Of equal importance are investigations examining the development of these pathologic conditions, from birth to maturity, and their associated disturbances in neurochemical and endocrine processes. A thorough understanding of gene expression in localized brain areas and the contribution of various transcription factors to this process should allow the identification and development of methods that are useful in the treatment, as well as prevention, of disturbed patterns of nutrient intake, fat deposition, and body weight gain.
Leibowitz
S F
SF
Rockefeller University, New York, New York 10021.
D000818:Animals; D004734:Energy Metabolism; D005246:Feedback; D005247:Feeding Behavior / Q000187:drug effects / Q000502:physiology*; D019004:Galanin; D015870:Gene Expression; D006801:Humans; D007031:Hypothalamus / Q000187:drug effects / Q000502:physiology*; D007328:Insulin / Q000502:physiology; D009478:Neuropeptide Y / Q000494:pharmacology / Q000502:physiology*; D009479:Neuropeptides / Q000096:biosynthesis* / Q000494:pharmacology / Q000502:physiology*; D009490:Neurosecretory Systems / Q000187:drug effects / Q000502:physiology*; D010455:Peptides / Q000494:pharmacology / Q000502:physiology*; D015398:Signal Transduction; D013256:Steroids / Q000494:pharmacology
D007328:Insulin; D009478:Neuropeptide Y; D009479:Neuropeptides; D010455:Peptides; D013256:Steroids; D019004:Galanin